Acute Myeloid Leukemia Aml Pipeline Insight

DelveInsight’s, “Acute Myeloid Leukemia - Pipeline Insight, 2022,” report provides comprehensive insights about 260+ companies and 260+ pipeline drugs in Acute Myeloid Leukemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Geography Covered

  • Global coverage

Acute Myeloid Leukemia Understanding

Acute Myeloid Leukemia: Overview

Acute myeloid leukemia (AML) is the most common leukemia among the adult population and accounts for about 80% of all cases. It is characterized by clonal expansion of immature "blast cells" in the peripheral blood and bone marrow resulting in ineffective erythropoiesis and bone marrow failure. With recent advancements in the management guidelines, the cure rates have increased up to 15% in patients older than 60 years and about 40% in patients below 60 years of age. Leukemias are clonal disorders, which means that cancer arises from a change in one original cell. In AML, this occurs in a hematopoietic stem cell, specifically a myeloblast. A myeloblast is an immature precursor cell found in the bone marrow. This means that a myeloblast will change (mature or differentiate) into a healthy white blood cell called an agranulocyte or a monocyte. In AML, myeloblasts do not mature, and grow and multiply out-of-control. Because myeloblasts are immature cells, they cannot perform the normal functions of mature blood cells.

 

"Acute Myeloid Leukaemia - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acute Myeloid Leukaemia pipeline landscape is provided which includes the disease overview and Acute Myeloid Leukaemia treatment guidelines. The assessment part of the report embraces, in depth Acute Myeloid Leukaemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute Myeloid Leukaemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

  • The companies and academics are working to assess challenges and seek opportunities that could influence R&D Acute Myeloid Leukaemia. The therapies under development are focused on novel approaches to treat/improve Acute Myeloid Leukaemia.
  • In January 2021 Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, and GlycoMimetics announced APL-106 (uproleselan) has been granted Breakthrough Therapy Designation (BTD) from the China National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) for the treatment of relapsed/refractory acute myeloid leukemia (AML).
  • In January 2022, Astex Pharmaceuticals, Inc. announced that the European Commission (EC) has granted orphan-drug designation (ODD) to the oral fixed dose combination of decitabine and cedazuridine (ASTX727) for the treatment of Acute Myeloid Leukemia (AML).


Acute Myeloid Leukaemia Emerging Drugs

Omidubicel: Gamida Cell

Omidubicel is an advanced cell therapy under development as a potential life-saving allogeneic hematopoietic stem cell (bone marrow) transplant solution for patients with hematologic malignancies (blood cancers). Omidubicel is the first bone marrow transplant product to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration and has also received Orphan Drug Designation in the U.S. and EU

 

Uproleselan: GlycoMimetics

Uproleselan (GMI-1271) is designed to block E-selectin (an adhesion molecule on cells in the bone marrow) from binding with AML cells as a targeted approach to disrupting well-established mechanisms of leukemic cell resistance within the bone marrow microenvironment. Preclinical research points to the drug's potential role in moving cancerous cells out of the protective environment of the bone marrow where they hide and escape the effects of chemotherapy. In preclinical studies using animal models of AML, the results of which were presented at meetings of the American Society of Hematology (ASH), GMI-1271 was also associated with a reduction of chemotherapy-induced neutropenia and chemotherapy-induced mucositis. Currently, the drug is in Phase III stage of clinical trial evaluation for the treatment of Relapsed/Refractory Acute Myeloid Leukemia

 

ALT 803: ImmunityBio

The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the development, maintenance, and function of the natural killer (NK) and T cells. ALT 803 is a novel IL-15 superagonist complex consisting of an IL-15 mutant (IL-15N72D) bound to an IL-15 receptor α/IgG1 Fc fusion protein. Its mechanism of action is direct specific stimulation of CD8+ T cells and NK cells through beta gamma T-cell receptor binding (not alpha) while avoiding T-reg stimulation.     ALT 803 has improved pharmacokinetic properties, longer persistence in lymphoid tissues and enhanced anti-tumor activity compared to native, non-complexed IL-15 in vivo. It is currently being evaluated in Phase II clinical trial to treat AML

 

BPX-501: Bellicum Pharmaceuticals

BPX-501 is an adjunct T cell therapy administered after allogeneic HSCT, comprising genetically modified donor T cells incorporating Bellicum’s CaspaCIDe safety switch. It is designed to provide a safety net to eliminate alloreactive BPX-501 T cells (via administration of activator agent rimiducid) should uncontrollable GvHD or other T-cell mediated complications occur. This enables physicians to more safely perform stem cell transplants by administering BPX-501 engineered T cells to speed immune reconstitution, provide control over viral infections and enhance Graft-versus-leukemic effect without unacceptable GvHD risk. The ongoing BP-004 clinical study of BPX-501 is being conducted at transplant centers in the U.S. and Europe. Concurrently, Bellicum Pharmaceuticals have reduced and expect to continue to reduce the rivo-cel related activities

Further product details are provided in the report……..

Acute Myeloid Leukaemia: Therapeutic Assessment

This segment of the report provides insights about the Acute Myeloid Leukaemia drugs segregated based on following parameters that define the scope of the report, such as:

 

Major Players in Acute Myeloid Leukaemia

There are approx. 260+ key companies which are developing the therapies Acute Myeloid Leukaemia. The companies which have their Acute Myeloid Leukaemia drug candidates in the most advanced stage, i.e preregistration include Gamida Cell

 

Phases

DelveInsight’s report covers around 260+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of 
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Route of Administration

Acute Myeloid Leukaemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as 

  • Oral
  • Intravenous
  • Subcutaneous

 

Molecule Type

Products have been categorized under various Molecule types such as

  • Small molecule
  • Cell Therapy
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Acute Myeloid Leukemia (AML): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acute Myeloid Leukemia (AML) therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute Myeloid Leukemia (AML) drugs.

Acute Myeloid Leukemia (AML) Report Insights

  • Acute Myeloid Leukemia (AML) Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Acute Myeloid Leukemia (AML) Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Acute Myeloid Leukemia (AML) drugs?
  • How many Acute Myeloid Leukemia (AML) drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acute Myeloid Leukemia (AML)?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Acute Myeloid Leukemia (AML) therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Acute Myeloid Leukemia (AML) and their status?
  • What are the key designations that have been granted to the emerging drugs?

 

Introduction

Executive Summary

Acute Myeloid Leukaemia: Overview

  • What is Acute Myeloid Leukaemia?
  • Types of Acute Myeloid Leukaemia
  • Causes
  • Epidemiology and Risk Factors
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Acute Myeloid Leukaemia– DelveInsight’s Analytical Perspective

Late Stage Products (Preregistration)

  • Comparative Analysis

Omidubicel: Gamida Cell

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase III)

  • Comparative Analysis

Uproleselan: GlycoMimetics

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

  • Comparative Analysis

ALT 803: ImmunityBio

  • Product Description
  • Research and Development
  • Product Development Activities

Early Stage Products (Phase I)

JNJ-75276617: Janssen Research & Development, LLC

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Preclinical Stage Products

  • Comparative Analysis

AB001: Agastiya Biotech

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Acute Myeloid Leukaemia Key Companies

Acute Myeloid Leukaemia Key Products

Acute Myeloid Leukaemia- Unmet Needs

Acute Myeloid Leukaemia- Market Drivers and Barriers

Acute Myeloid Leukaemia- Future Perspectives and Conclusion

Acute Myeloid Leukaemia Analyst Views

Acute Myeloid Leukaemia Key Companies

Appendix

List of Table

Table 1: Total Products for Acute Myeloid Leukemia (AML)

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Acute Myeloid Leukemia (AML)

Figure 2: Late Stage Products

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products      

• GlycoMimetics
• CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
• Takeda Oncology
• Orca Bio
• Gilead Sciences
• Actinium Pharmaceuticals
• Kronos Bio
• Bristol-Myers Squibb
• ImmunityBio
• Bellicum Pharmaceuticals
• TC BioPharm
• Syros Pharmaceuticals
• Armaceutica
• Teva Pharmaceutical Industries
• New Epsilon Innovation Limited
• MediGene
• TC Biopharm
• PersonGen BioTherapeutics
• Oncoceutics
• Janssen Research & Development, LLC
• Immune-Onc Therapeutics
• Novartis
• Jasper Therapeutics
• Agastiya Biotech
• Poseida Therapeutics
• Molecular Partners
• Allogene Therapeutics
• Allogene therapeutics

 

 

Forward to Friend

Need A Quote